Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for ApoCIII Reduction
NCT02083510Phase 1Completed
- Sponsor
- Scripps Research
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of colchicine in hypertriglyceridemia, sponsored by Scripps Research. Primary endpoints: Reduction in Apolipoprotein CIII levels at 6 weeks, Reduction of triglycerides levels at 6 weeks and 1 more. Started Feb 2014; status: completed.
02
Drugs
colchicine
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02083510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083510.